A Phase 1/2 interventional study of Renishaw Drug Delivery System in Parkinson Disease, Movement Disorders and Neuro-Degenerative Disease, sponsored by Renishaw. Status unknown at 3 sites in 2 countries. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-03-23.
Sponsored by Renishaw · Phase 1/2, Interventional, and Treatment
This study is a follow up to the HP-CD-CL-2002 clinical study. It evaluates the long-term safety in patients with Parkinson's disease after implantation of an investigational drug delivery system (DDS) with or without infusions of CDNF. All patients will have at least the port explanted.
A patients participation in the study will last for up to 4 years and will include up to nine visits:
Study examinations and assessments:
For more information: https://treater.eu/clinical-study/
4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.
This study's enrollment of 15 is below the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →This is the only study on the registry with Renishaw as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patients who:
Exclusion Criteria:
As this is the follow up study, there are no arms
Device: Renishaw Drug Delivery System
Device that allows pharmaceuticals to be delivered into the brain is to be assessed over a period of time to inform of the long term safety of the implanted device.
Incidence of treatment-emergent adverse events (AEs)[safety-tolerability]
Total number, causality and severity of adverse events at any time during the study period
Time frame: Until study completion, up to month 58
Change in Electrocardiogram (ECG): Ventricular rate (bpm), [safety-tolerability]
Changes in electrical activity of heartbeat measured by electrocardiogram: Ventricular rate (bpm),
Time frame: Week 71 and Month 25
Change in Electrocardiogram (ECG): PR (pulse rate) interval, qRS duration, QT, QTc (msec) [safety-tolerability]
Changes in electrical activity of heartbeat measured by electrocardiogram: PR interval (msec), QRS duration (msec), QT (msec), QTc (msec)
Time frame: Week 71 and Month 25
Change in Beck Depression Inventory (BDI) score [safety-tolerability]
Assessment of change in depression using Beck Depression Inventory (BDI) score: Sadness: Pessimism; Past Failure; Loss of pleasure; Guilty feelings; Punishment Feelings; Self-dislike; Self-criticalness;Suicidal thoughts or wishes; Crying; Agitation; Loss of interest; Indecisiveness;Worthlessness; Loss of energy; Changes in sleeping pattern; Irritability; Changes in appetite; Concentration difficulty; Tiredness or fatique; Loss of interest in sex. Rated on a 4-point scale ranging from 0 to 3 based on severity of each item (0=low intensity; 3=highest intensity). The maximum total score is 63.
Time frame: Week 71 and Month 25
Change in Questionnaire for impulsive-compulsive disorder in Parkinson's disease rating scale (QUIP_RS) [safety-tolerability]
Assessment of changes in impulsive-compulsive disorders using QUIP_RS. Questions scored 0-4 (0=never; 4=very often) on gambling, sex, buying, eating, performing tasks/hobbies, repeating simple activities, and taking Parkinson's disease medication. Total QUIP-RS Score 0-112 Assessment of changes in impulsive-compulsive disorders using QUIP_RS. Questions scored 0-4 (0=never; 4=very often) on gambling, sex, buying, eating, performing tasks/hobbies, repeating simple activities, and taking Parkinson's disease medication. Total QUIP-RS Score 0-112 Assessment of changes in impulsive-compulsive disorders using QUIP_RS. Questions scored 0-4 (0=never; 4=very often) on gambling, sex, buying, eating, performing tasks/hobbies, repeating simple activities, and taking Parkinson's disease medication. Total QUIP-RS Score 0-112
Time frame: Week 71 and Month 25
Change in Montreal cognitive assessment (MoCA) [safety-tolerability]
Assessment of change in cognitive domains using MoCA test: attention and, concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The total possible score is 30 points; a score of 26 or above is considered normal.
Time frame: Week 71 and Month 25
Changes in physical examination: anatomic findings [safety-tolerability]
Changes in anatomic findings found in physical examination of the following body systems: general inspection/upper extremities; head, eyes, ears, nose, throat, and superficial cervial lymph notes; neck, shoulders, back; chest and lungs; cardiovascular; abdomen; lower extremities
Time frame: Week 71, and Months 25, 34, 58
Changes in physical examination: clinical standard neurological examination
A clinical standard neurological examination by study investigator. Changes in motor function, sensory function, cranial nerve function (visual fields), cortical functions and reflexes are followed in the examination, scored as normal - abnormal without clinical relevance - abnormal with clinical relevance
Time frame: Week 71, and Months 25, 34, 58
Changes in vital signs: blood pressure [safety-tolerability]
Changes in blood pressure during the study , measured as systolic and diastolic blood pressure (in mmHg)
Time frame: Weeks 55, 57, 58, 75
Changes in vital signs: pulse rate [safety-tolerability]
Changes in pulse rate during the study (in beats per minute)
Time frame: Weeks 55, 57, 58, 75
Changes in vital signs: body temperature [safety-tolerability]
Changes in body temperature during the study (in degrees celcius)
Time frame: Weeks 55, 57, 58, 75
Changes in vital signs: body weight [safety-tolerability]
Changes in body weight during the study (in kilograms)
Time frame: Weeks 55, 57, 58, 75
Changes in vital signs: body mass index (BMI) [safety-tolerability]
Changes in body mass index during the study (in kg/m\^2)
Time frame: Weeks 55, 57, 58, 75
Changes in clinical laboratory safety screen: clinical chemistry [safety-tolerability]
Changes in laboratory variables for clinical chemistry (Na, K, Urea, creatinine, creatine kinase, Ca, Bilirubin, IgG (Immunoglobulin G), Albumin, ALP(Alkaline phosphatase), ALT (Alanine transaminase), AST (Aspartate transaminase))
Time frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: haematology - haemoglobin [safety-tolerability]
Changes in laboratory variables for haematology: hemoglobin (g/L). Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Time frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: haematology - haematocrit [safety-tolerability]
Changes in laboratory variables for haematology: hematocrit (%, ratio of red blood cell volume to total blood volume). Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Time frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: haematology - red blood cell (RBC) count [safety-tolerability]
Changes in laboratory variables for haematology: RBC count (10E12/L). Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Time frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: mean cell volume (MCV) of red blood cells [safety-tolerability]
Changes in laboratory variables for haematology: MCV of red blood cells (fL). Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Time frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: mean cell haemoglobin of RBC (MHC) [safety-tolerability]
Changes in laboratory variables for haematology: MCH (Mean cell hemoglobin) (pg). Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Time frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: Platelet count [safety-tolerability]
Changes in laboratory variables for haematology: Platelet count (10E9/L). Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Time frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: white blood call (WBC) count [safety-tolerability]
Changes in laboratory variables for haematology: Cell counts (10E9/L) for total WBC, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Time frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: activated partial thromboplastin time (aPTT) [safety-tolerability]
Changes in laboratory variables for haematology: aPTT (sec) . Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Time frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: International Normalised Ratio (INR) [safety-tolerability]
Changes in laboratory variables for haematology: INR (standardized prothrombin time) to determine the effects of oral anticoagulants on the clotting system. Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Time frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: urinanalysis [safety-tolerability]
Changes in laboratory variables for urinanalysis (blood/erythrocytes, glucose, ketones, leukocytes, nitrites, pH, protein) studied by dipstick and scored 0-3. Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Time frame: Weeks 53, 55, 57, 58, 71 and Month 25
Formation of anti-CDNF antibodies [safety-tolerability]
Formation and change in anti-CDNF antibody concentration (in ng/ml).
Time frame: Weeks 58, 78 and Month 25
Device related occurrence of adverse device effects [safety-tolerability]
Occurrence of adverse device effects (ADE) at any time of the study period, for either the whole system or the individual sub systems (guide tubes/catheters, subcutaneous components, port), serious adverse device effect (SADE) including long term effects, neurological deficit (seizures), infection (local to components, in CNS), severe skin breakdown or necrosis requiring component removal life threatening or major (requiring intervention) intracerebral haemorrhage.
Time frame: Week 49 and Month 58
Change in UPDRS (Unified Parkinson's Disease Rating Scale) Part III motor score [efficacy]
Changes in severity of PD (Parkinson's disease) motor symptoms assessed by UPDRS Part III motor scores (each scored 0-4; 0=none, 4=severe): Speech; facial expression; tremor a rest; Tremor of hands; rigidity; firger taps; hand movelents; alternating movement of hands; leg agility; rising from chair; posture; gait; postural stability; body bradykinesia and hypokinesia. The total score, the sum of scores received from 27 assessments, is 0 - 108
Time frame: Week 71 and Month 25
Change in TUG (Timed Up and Go) test [efficacy]
Changes in mobility assessed by TUG test (in minutes and seconds).
Time frame: Week 71 and Month 25
Change in UPDRS Total score (Part I-IV) [efficacy]
Change in severity of PD non-motor and motor symptoms assessed by UPDRS Part I-IV total scores (Parts I, II and IV in ON-state; Part III in OFF-state): Part 1 (scored 0-16) Mentation, behaviour and mood. Part 2 (scored 0-52) Activities of daily living. Part 3 (scored 0-108) Motor examination. Part 4 (scored 0-23) Complications of therapy. The total score is 0-199 (0=totally healthy; 199=worst possible).
Time frame: Week 71 and Month 25
Change in home diary score [efficacy]
Change in functional status of the patient's dyskinesias assessed by home diary score for three-day period. Each half hour is scored: sleep, OFF, ON without dyskinesias, ON with non-troublesome dyskinesias, ON with troublesome dyskinesias. The total time in each state over 3 days is recorded (in hours). The total "bad time" is defined as "OFF time" and "ON time with troublesome dyskinesia". The total "good time" is defined as "ON time without dyskinesia" or "ON time with non-troublesome dyskinesia".
Time frame: Weeks 40, 45, 49, 53, 57, 58, 61, 65, 71, and Month 25
Change in PDQ-39 (Parkinson's Disease Questionnaire) score [efficacy]
Changes in health and daily activity assessed by a self-administered PDQ-39 questionnaire comprising of 39 questions related to eight key areas of health in Parkinson's patients: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication and bodily discomfort. Each question is evaluated on a scale of five terms "Never", "Occasionally", "Sometimes", "Often" or "Always or cannot do at all".
Time frame: Week 71 and Month 25
Change in CGI-I (Clinical Global Impression - Improvement) scale [efficacy]
Change in mental status as measured by CGI-I scale rated by the clinical on a seven-point scale 1-7 (1=very much improved, 4=no change, 7=very much worse).
Time frame: Weeks 40, 45, 49, 53, 57, 58, 61, 65, 71, and Month 25
Healing of patient skin after port removal
Any Adverse Events (AEs) or Serious Adverse Events (SAEs) related to the skin condition once the port has been removed
Time frame: Month 25, 34 and 58
Change in DAT (dopamine transporter)-PET imaging [exploratory]
Change in caudate and putamen DAT availability using PET imaging
Time frame: Week 63
Change in daily activity measurement [exploratory]
Change in daily activity measured by Parkinson's KinetiGraph™ (PKG™) Data Logger: dyskinesia, bradykinesia, tremor, immobility plot, fluctuation score. The PKG units are: Bradykinesia score in % from normal controls, and, Dyskinesia score in % from normal controls. The Fluctuation and Dyskinesia score (FDS) for normal controls is in the range of 7.8-12.8: a lower score indicates bradykinesia and a higher score indicates dyskinesia.
Time frame: Weeks 58, 71 and Month 25
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.